BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 6681731)

  • 1. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.
    Campbell AB; Kalman SM; Jacobs C
    Cancer Treat Rep; 1983 Feb; 67(2):169-72. PubMed ID: 6681731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relationship between plasma and urinary platinum pharmacokinetics with cisplatin nephrotoxicity in breast cancer patients].
    Guo JH
    Zhonghua Zhong Liu Za Zhi; 1992 Mar; 14(2):150-3. PubMed ID: 1618086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations.
    Kelsen DP; Alcock N; Young CW
    Am J Clin Oncol; 1985 Feb; 8(1):77-80. PubMed ID: 4039530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
    Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
    Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
    Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
    Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors.
    Lagrange JL; Médecin B; Etienne MC; Pivot X; Cassuto-Viguier E; Renée N; Thyss A; Ferrero JM; Otto J; François E; Milano G
    Pharmacotherapy; 1997; 17(6):1246-53. PubMed ID: 9399607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.
    Ostrow S; Egorin MJ; Hahn D; Markus S; Aisner J; Chang P; LeRoy A; Bachur NR; Wiernik PH
    Cancer Treat Rep; 1981; 65(1-2):73-8. PubMed ID: 6784924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical multivariate statistical analysis of nephrotoxicity induced by cisplatin].
    Ding DC
    Zhonghua Zhong Liu Za Zhi; 1992 Jan; 14(1):64-6. PubMed ID: 1396050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The protective effects of two hydration protocols against cisplatin nephrotoxicity].
    Guo JH; Song ST; Xu ZL
    Zhonghua Zhong Liu Za Zhi; 1994 Jan; 16(1):56-8. PubMed ID: 8033751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
    Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
    Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
    Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
    Ahn JH; Kang YK; Kim TW; Bahng H; Chang HM; Kang WC; Kim WK; Lee JS; Park JS
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):104-10. PubMed ID: 12172973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)].
    Gory-Delabaere G; Cupissol D; Brès J; Gau F; Constans B; Nouguier-Soulé J
    J Soc Biol; 1999; 193(1):49-55. PubMed ID: 10851556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
    Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
    Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
    Bhalla KN; Kumar GN; Walle UK; Ibrado AM; Javed T; Stuart RK; Reed C; Arbuck SG; Walle T
    Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
    Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
    Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.